Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Differences in Expansion Potential of Naive Chimeric Antigen Receptor T Cells from Healthy Donors and Untreated Chronic Lymphocytic Leukemia Patients
Heidelberg Univ Hosp, Dept Internal Med 5, GMP Core Facil, Cellular Immunotherapy, Heidelberg, Germany..
Heidelberg Univ Hosp, Dept Internal Med 5, GMP Core Facil, Cellular Immunotherapy, Heidelberg, Germany..
Heidelberg Univ Hosp, Dept Internal Med 5, GMP Core Facil, Cellular Immunotherapy, Heidelberg, Germany..
Heidelberg Univ Hosp, Dept Internal Med 5, GMP Core Facil, Cellular Immunotherapy, Heidelberg, Germany..
Show others and affiliations
2018 (English)In: Frontiers in Immunology, ISSN 1664-3224, E-ISSN 1664-3224, Vol. 8, article id 1956Article in journal (Refereed) Published
Abstract [en]

Introduction: Therapy with chimeric antigen receptor T (CART) cells for hematological malignancies has shown promising results. Effectiveness of CART cells may depend on the ratio of naive (T-N) vs. effector (T-E) T cells, TN cells being responsible for an enduring antitumor activity through maturation. Therefore, we investigated factors influencing the T-N/T-E ratio of CART cells.

Materials and methods: CART cells were generated upon transduction of peripheral blood mononuclear cells with a CD19.CAR-CD28-CD137zeta third generation retroviral vector under two different stimulating culture conditions: anti-CD3/anti-CD28 antibodies adding either interleukin (IL)-7/1L-15 or IL-2. CART cells were maintained in culture for 20 days. We evaluated 24 healthy donors (HDs) and 11 patients with chronic lymphocytic leukemia (CLL) for the composition of cell subsets and produced CART cells. Phenotype and functionality were tested using flow cytometry and chromium release assays.

Results: IL -7/1L-15 preferentially induced differentiation into T-N, stem cell memory (T-SCM: naive CD27+ CD95+), CD4+ and CXCR3+ CART cells, while IL-2 increased effector memory (T-EM), CD56+ and CD4+ T regulatory (T-Reg) CART cells. The net amplification of different CART subpopulations derived from HDs and untreated CLL patients was compared. Particularly the expansion of CD4+ CART(N) cells differed significantly between the two groups. For HDs, this subtype expanded >60-fold, whereas CD4+ CART(N) cells of untreated CLL patients expanded less than 10-fold. Expression of exhaustion marker programmed cell death 1 on CART(N) cells on day 10 of culture was significantly higher in patient samples compared to HD samples. As the percentage of malignant B cells was expectedly higher within patient samples, an excessive amount of B cells during culture could account for the reduced expansion potential of CART(N) cells in untreated CLL patients. Final T-N/T-E ratio stayed <0.3 despite stimulation condition for patients, whereas this ratio was >2 in samples from HDs stimulated with IL-7/1L-15, thus demonstrating efficient CART(N) expansion.

Conclusion: Untreated CLL patients might constitute a challenge for long-lasting CART effects in vivo since only a low number of T-N among the CART product could be generated. Depletion of malignant B cells before starting CART production might be considered to increase the T-N/T-E ratio within the CART product.

Place, publisher, year, edition, pages
FRONTIERS MEDIA SA , 2018. Vol. 8, article id 1956
Keywords [en]
chimeric antigen receptor, immunotherapy, CD19, T cell subpopulations, naive T cells, cytokines, chronic lymphocytic leukemia, T cell expansion
National Category
Medical and Health Sciences
Identifiers
URN: urn:nbn:se:uu:diva-341573DOI: 10.3389/fimmu.2017.01956ISI: 000419713000002OAI: oai:DiVA.org:uu-341573DiVA, id: diva2:1181953
Available from: 2018-02-12 Created: 2018-02-12 Last updated: 2018-02-12Bibliographically approved

Open Access in DiVA

fulltext(3842 kB)60 downloads
File information
File name FULLTEXT01.pdfFile size 3842 kBChecksum SHA-512
d13471b78425c21a69082026ca9c10437525d8744266e021d36ad3aacdf5c8fd75f3051bd2c156cb9197bf96c51752eccc052d6ca9bad3e9baff91caca5082e2
Type fulltextMimetype application/pdf

Other links

Publisher's full text

Search in DiVA

By author/editor
Loskog, Angelica S.
By organisation
Clinical ImmunologyScience for Life Laboratory, SciLifeLab
In the same journal
Frontiers in Immunology
Medical and Health Sciences

Search outside of DiVA

GoogleGoogle Scholar
Total: 60 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 37 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf